Vertex Pharmaceuticals Inc down (U.S.)$2.83

Vertex Pharmaceuticals Inc closed sharply lower Thursday, dropping (U.S.)$2.83 or 1.87% to (U.S.)$148.54. Over the last five days, shares are unchanged, but have gained 101.63% over the last year to date. This security has outperformed the S&P 500 by 37.35% during the last year.

Key company metrics

Open(U.S.) $150.93

Previous close(U.S.) $151.37

High(U.S.) $152.41

Low(U.S.) $148.52

Bid / Ask(U.S.) $0.00 / (U.S.) $155.90

YTD % change+101.63%

Volume1,019,238

Average volume (10-day)1,061,515

Average volume (1-month)2,237,933

Average volume (3-month)1,935,727

52-week range(U.S.) $71.46 to (U.S.) $167.86

Beta1.77

Trailing P/E143.77×

P/E 1 year forward94.13×

Forward PEG1.38×

Indicated annual dividend--

Dividend yield0.00%

Trailing EPS(U.S.) $1.03

Updated August 17 4:00 PM EDT. Delayed by at least 15 minutes.

Key company metrics

Open(U.S.) $150.93

Previous close(U.S.) $151.37

High(U.S.) $152.41

Low(U.S.) $148.52

Bid / Ask(U.S.) $0.00 / (U.S.) $155.90

YTD % change+101.63%

Volume1,019,238

Average volume (10-day)1,061,515

Average volume (1-month)2,237,933

Average volume (3-month)1,935,727

52-week range(U.S.) $71.46 to (U.S.) $167.86

Beta1.77

Trailing P/E143.77×

P/E 1 year forward94.13×

Forward PEG1.38×

Indicated annual dividend--

Dividend yield0.00%

Trailing EPS(U.S.) $1.03

Updated August 17 4:00 PM EDT. Delayed by at least 15 minutes.

About

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing

Continue reading

and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.

Restrictions

All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. Thomson Reuters is not liable for any errors or delays in Thomson Reuters content, or for any actions taken in reliance on such content. ‘Thomson Reuters’ and the Thomson Reuters logo are trademarks of Thomson Reuters and its affiliated companies.